Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Safety Study of Single Dose Allogeneic Bone Marrow Derived MSCs for Steroid Refractory Acute Graft vs. Host Disease

NCT05443464 is registered in ClinicalTrials.gov with Ossium Health, Inc. as lead sponsor.

NCT NCT05443464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05443464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Safety Study of Single Dose Allogeneic Bone Marrow Derived MSCs for Steroid Refractory Acute Graft vs. Host Disease
Lead sponsor
Ossium Health, Inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
June 5, 2023
Completion date
October 14, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gvhd,acute